Rapid Micro Biosystems (RPID) Non-Current Debt (2020 - 2026)

Rapid Micro Biosystems (RPID) posted Non-Current Debt of $19.1 million for Q1 2026, up 0.8% sequentially from $18.9 million in Q4 2025.

Rapid Micro Biosystems (RPID) Non-Current Debt (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems has reported Non-Current Debt for 4 years, with the latest figure at $19.1 million in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.1 million (changed N/A YoY) and the FY2025 annual result came in at $18.9 million, changed N/A from the prior year.
Non-Current Debt grew to $19.1 million in Q1 2026 per RPID's latest filing, from $18.9 million in the prior quarter.
Over five years, Non-Current Debt peaked at $19.1 million in Q1 2026 and troughed at $18.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	29.60 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	14.19 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	26.17 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	10.92 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	598.70 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	10.09 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	7.34 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	1.65 Bn
10	Rapid Micro Biosystems	80.26 Mn	60.49 Mn	1.21 Mn	19.14 Mn

Download Data